Jeffrey E. Depp Image

Jeffrey E. Depp

IP & Innovation Policy

University of Pittsburgh

Jeff is a registered patent attorney and an intellectual property and innovation policy professional with a unique combination of training and real world experience. Jeff has done policy work for trade organizations, professional societies and other organizations. He has worked in university technology transfer, the pharmaceutical industry, the law and the non-profit sector. Jeff is also currently a PhD candidate at the University of Pittsburgh Graduate School of Public and International Affairs (GSPIA). His dissertation consists of an analysis of the current state of U.S. innovation from an Austrian economics perspective. His broader research interests include innovation policy at the intersection of economics, intellectual property law and antitrust law. In addition, he is a Thomas Edison Innovation Law and Policy Fellow at the Center for Intellectual Property x Innovation Policy (C-IP 2 ) at the Antonin Scalia Law School at George Mason University.

Jeff has a bachelor’s degree in chemical and biomedical engineering with concentrations in molecular biology and fermentation technology and from Carnegie Mellon University. He also has a master’s degree in industrial administration (business) from Carnegie Mellon where he concentrated on international management, marketing and finance. He earned his law degree from the Duquesne University School of Law with a focus on intellectual property law.

Recent Articles by Jeffrey E. Depp

Biden Administration Moves Ahead with Its Unconstitutional Drug Pricing Regime That is Doomed to Fail

Last week, the White House announced that the manufacturers of all ten of the drugs singled out by the Centers for Medicare and Medicaid Services (CMS) and its drug price negotiation program (DPNP) have “agreed” to participate therein. The announcement concerns the manufacturers reluctantly agreeing to subject themselves to the sweeping drug price “negotiation” provisions of the Inflation Reduction Act (IRA), which was passed last year. Those provisions empower CMS to essentially dictate whatever price it pleases for a set of prescription drugs, the first ten of which were announced at the end of August.

Past Events with Jeffrey E. Depp

Life Sciences Masters™ 2023

Held October 16-18, 2023